切换至 "中华医学电子期刊资源库"

中华肥胖与代谢病电子杂志 ›› 2026, Vol. 12 ›› Issue (02) : 85 -93. doi: 10.3877/cma.j.issn.2095-9605.2026.02.001

论著

TyG-BMI与WHtR评估超重及肥胖人群内脏脂肪面积的价值及诊断切点
郭楠1, 李珊珊1, 赵丹1, 薛露露1, 李宇1,2, 李炎妮1,2, 杨彩彩1,2, 贾爱华1,2,()   
  1. 1716000 陕西延安,延安大学延安医学院
    2719000 陕西榆林,陕西省榆林市第一医院内分泌科
  • 收稿日期:2026-05-11 出版日期:2026-05-31
  • 通信作者: 贾爱华
  • 基金资助:
    北京医学奖励基金会(YXJL-2024-1691-0615)

The value and diagnostic cutoffs of TyG-BMI and WHtR for assessing visceral fat area in overweight and obese populations

Nan Guo1, Shanshan Li1, Dan Zhao1, Lulu Xue1, Yu Li1,2, Yanni Li1,2, Caicai Yang1,2, Aihua Jia1,2,()   

  1. 1Yan'an University School of Medicine
    2Department of Endocrinology, Yulin First Hospital of Shaanxi Province, Yulin 719000, China
  • Received:2026-05-11 Published:2026-05-31
  • Corresponding author: Aihua Jia
引用本文:

郭楠, 李珊珊, 赵丹, 薛露露, 李宇, 李炎妮, 杨彩彩, 贾爱华. TyG-BMI与WHtR评估超重及肥胖人群内脏脂肪面积的价值及诊断切点[J/OL]. 中华肥胖与代谢病电子杂志, 2026, 12(02): 85-93.

Nan Guo, Shanshan Li, Dan Zhao, Lulu Xue, Yu Li, Yanni Li, Caicai Yang, Aihua Jia. The value and diagnostic cutoffs of TyG-BMI and WHtR for assessing visceral fat area in overweight and obese populations[J/OL]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2026, 12(02): 85-93.

目的

比较甘油三酯-葡萄糖指数联合体重指数(TyG-BMI)与腰高比(WHtR)在超重及肥胖人群中诊断内脏脂肪面积(VFA)的效能,并探讨其性别差异,为临床筛查中心性肥胖及代谢风险提供简易、精准的评估工具。

方法

纳入117名超重及肥胖患者,以VFA的四分位数(113.60 cm2、146.30 cm2、190.10 cm2)为分组界值,分为S1至S4四组。收集人体测量学、血清学及胰岛素抵抗相关复合指标,采用Pearson相关性分析评估各指标与VFA的相关性,通过ROC曲线分析比较各指标诊断高VFA的效能,并进行性别亚组分析。采用临床决策曲线分析(DCA)评估各指标的净临床获益,并计算阳性预测值(PPV)与阴性预测值(NPV)。

结果

S4组在体重(107.07±17.40 vs 80.34±10.28)、腰围(116.31±12.13 vs 97.60±8.81)、腰高比(0.69±0.07 vs 0.59±0.05)、TyG-BMI(340.34±45.48 vs 265.30±31.29)高于S1组,血压(135.83±16.50 vs 125.27±18.74)、肝功能(24.90 vs 22.45)及脂肪肝(355.34±42.59 vs 293.20±36.42)程度等方面均高于S1组(P<0.05)。相关性分析显示,TyG-BMI(r=0.559)与腰高比(r=0.587)与VFA呈正相关(P<0.05)。性别亚组分析显示,TyG-BMI与腰高比在不同VFA切点下的截断值存在性别差异,男性TyG-BMI切点为298.12~315.89,女性为263.76~283.88,男性腰高比切点为0.62~0.65,女性为0.58~0.63。DCA显示,TyG-BMI的净临床获益最大,优于腰高比、腰围及BMI。以VFA≥100 cm2为金标准,TyG-BMI>298.64时PPV达97.7%,高于腰高比>0.62(94.5%)、腰围>103.7 cm(93.8%)及BMI>31.11(94.8%);但四项指标的NPV均偏低(24.7%~37.5%),提示排除能力有限。

结论

TyG-BMI与WHtR可以作为超重及肥胖人群VFA的评估指标,但存在性别差异,当TyG-BMI>282.73(男性>298.12)及当WHtR>0.58(男性0.62)时,可作为内脏脂肪异常蓄积的早期预警指标,初步提示个体可能存在显著的内脏脂肪堆积,值得进一步进行VFA的检查及动态观察。TyG-BMI在筛查内脏型肥胖中具有最优的临床净获益和确诊效能,可作为高危人群的便捷筛查工具,但阴性结果时需联合其他指标进一步评估。

Objective

To compare the performance of triglyceride-glucose index combined with body mass index (TyG-BMI) and waist-to-height ratio (WHtR) in the diagnosis of visceral fat area (VFA) in overweight and obese people, and to explore their gender differences, so as to provide a simple and accurate assessment tool for clinical screening of central obesity and metabolic risk.

Methods

A total of 117 overweight and obese patients were enrolled. The quartiles of VFA (113.60 cm2, 146.30 cm2, 190.10 cm2)were used as the cut-off values and divided into four groups: S1 to S4. Anthropometric, serological and insulin resistance-related composite indicators were collected. Pearson correlation analysis was used to evaluate the correlation between each indicator and VFA. ROC curve analysis was used to compare the efficacy of each indicator in diagnosing high VFA, and gender subgroup analysis was performed. Clinical decision curve analysis (DCA) was used to evaluate the net clinical benefit of each index, and the positive predictive value (PPV) and negative predictive value (NPV) were calculated.

Results

The body weight (107.07±17.40 vs 80.34±10.28 ), waist circumference (116.31±12.13 vs 97.60±8.81), waist-to-height ratio (0.69±0.07 vs 0.59±0.05) and TyG-BMI (340.34±45.48 vs 265.30±31.29) in group S4 were higher than those in group S1. Blood pressure (135.83±16.50 vs 125.27±18.74), liver function (24.90 vs 22.45) and fatty liver (355.34±42.39 vs 293.20±36.42) were higher than those in S1 group (P<0.05). Correlation analysis showed that TyG-BMI (r=0.559 ) and waist-to-height ratio (r=0.587) were positively correlated with VFA (P<0.05). Gender subgroup analysis showed that the cut-off values of TyG-BMI and waist-to-height ratio at different VFA cut-off points. There were gender differences. The cut-off point of TyG-BMI was 298.12-315.89 in males and 263.76-283.88 in females. The cut-off point of waist-to-height ratio was 0.62-0.65 in males and 0.58-0.63 in females. DCA showed that TyG-BMI had the greatest net clinical benefit, which was better than waist-to-height ratio, waist circumference and BMI. Taking VFA ≥100 cm2 as the gold standard, PPV reached 97.7 % when TyG-BMI > 298.64, which was higher than waist-to-height ratio >0.62 (94.5%), waist circumference >103.7 cm (93.8%) and BMI >31.11 (94.8%). However, the NPV of the four indicators was low (24.7%-37.5%), suggesting that the exclusion ability was limited.

Conclusion

TyG-BMI and WHtR can be used as indicators of VFA in overweight and obese people, but there are gender differences. When TyG-BMI >282.73 (male >298.12) and WHtR >0.58 (male 0.62 ), It can be used as an early warning index for abnormal accumulation of visceral fat.it is preliminarily suggested that there may be significant visceral fat accumulation in individuals, which is worthy of further examination and dynamic observation of VFA.TyG-BMI has the best clinical net benefit and diagnostic efficacy in screening visceral obesity, and can be used as a convenient screening tool for high-risk groups, but negative results need to be further evaluated in combination with other indicators.

表1 S1~S4组间人体测量学指标及血清学指标基线资料比较
变量 S1组(n=30) S2组(n=29) S3组(n=29) S4组(n=29) P
年龄(岁) 37.67±7.64 33.48±7.56 35.76±11.47 31.21±7.80 0.034
男性[n(%)] 8(26.67) 8(27.59) 12(41.38) 13(44.83) 0.149
女性[n(%)] 22(73.33) 21(72.41) 17(58.62) 16(55.17)
身高(cm) 164.95±8.97 165.51±8.49 168.29±8.81 169.27±9.39 0.187
体重(kg) 80.34±10.28 87.39±14.37 95.87±20.81 107.07±17.40 <0.001
BMI(kg/m2 29.50±2.74 31.73±2.98 33.54±4.73 37.19±3.95 <0.001
腰围(cm) 97.60±8.81 101.64±10.46 108.35±14.11 116.31±12.13 <0.001
臀围(cm) 105.55±5.28 107.90±6.36 112.30±12.98 118.86±4.88 <0.001
腿围(cm) 60.78±7.95 62.04±9.79 62.49±7.79 66.81±5.76 0.027
腰臀比 0.92±0.07 0.94±0.08 0.97±0.09 0.98±0.08 0.053
腰高比 0.59±0.05 0.61±0.05 0.64±0.06 0.69±0.07 <0.001
收缩压(mmHg) 125.27±18.74 128.52±12.53 131.07±10.64 135.83±16.50 0.055
舒张压(mmHg) 83.20±12.31 82.69±10.64 86.24±8.73 89.76±13.66 0.077
心率(次/分) 88.40±10.83 91.24±17.85 89.17±14.12 93.41±13.38 0.535
体脂百分比(%) 31.51±4.00 36.14±2.69 38.87±4.18 44.84±4.71 <0.001
去脂体重(kg) 55.21±8.63 55.01±10.41 59.50±16.19 59.29±12.13 0.307
肌肉量(kg) 51.16±8.71 51.60±9.86 56.52±15.98 56.08±11.51 0.170
体脂含量(kg) 25.57±3.90 31.81±5.27 36.53±7.29 47.89±8.11 <0.001
HbA1c(%) 5.50±0.97 5.74±1.32 5.75±0.82 6.05±1.28 0.612
空腹血糖(mmol/L) 5.53±1.42 5.91±1.66 5.55±1.30 5.97±1.48 0.530
空腹C肽(ng/mL) 3.52±1.53 4.58±1.80 4.21±1.56 4.51±1.44 0.047
空腹胰岛素(μIU/ml) 17.33(11.73,22.61) 23.33(14.64,39.57) 19.89(13.23,31.56) 24.90(18.64,35.95) 0.171
LDL-C(mmol/L) 2.80±0.74 2.76±0.84 2.83±0.66 2.74±0.61 0.967
尿酸(μmol/L) 316.71±69.69 348.47±112.46 370.06±102.69 342.53±96.82 0.193
AST(U/L) 22.45(18.63,26.65) 25.30(19.25,38.40) 23.60(21.05,30.40) 24.80(18.85,44.20) 0.121
ALT(U/L) 23.00(16.73,36.75) 38.00(20.50,56.50) 28.00(19.00,43.50) 37.00(23.50,68.00) 0.061
CAP 293.20±36.42 329.24±52.70 337.28±38.95 355.34±42.59 <0.001
LSM 5.60(4.48,6.70) 5.90(4.60,11.45) 6.80(4.50,9.25) 8.70(6.90,12.30) 0.013
表2 S1~S4组间身体测量学复合指标及胰岛素抵抗指标基线资料比较
图1 身体测量学指标与人体体成分相关性热图注:WWR:体重与腰围比;WWI:腰围体重指数;TyG:甘油三酯-葡萄糖指数=Ln[TG(mg/dL)×FPG(mg/dL)/2]
图2 WHtR及TyG-BMI的ROC曲线。A:VFA第25百分位(113.60 cm2)为诊断标准时;B:VFA第50百分位(146.30 cm2)为诊断标准时;C:VFA第75百分位(190.10 cm2)为诊断标准时
表3 各诊断方式曲线下面积
图3 VFA第25百分位(113.60 cm2)为诊断标准时男性WHtR及TyG-BMI的ROC曲线。图4 VFA第25百分位(113.60 cm2)为诊断标准时女性WHtR及TyG-BMI的ROC曲线。图5 VFA第50百分位(146.30 cm2)为诊断标准时男性WHtR及TyG-BMI的ROC曲线。图6 VFA第50百分位(146.30 cm2)为诊断标准时女性WHtR及TyG-BMI的ROC曲线。图7 VFA第75百分位(190.10 cm2)为诊断标准时男性WHtR及TyG-BMI的ROC曲线。图8 VFA第75百分位(190.10 cm2)为诊断标准时女性WHtR及TyG-BMI的ROC曲线
表4 各诊断方式诊断WHtR曲线下面积
表5 各诊断方式诊断TyG-BMI曲线下面积
图9 TyG-BMI、腰高比、腰围及BMI预测内脏脂肪超标(100 cm2)临床决策曲线分析图
表6 各指标临床决策曲线的净获益
[1]
Zuo J, Huang Z, Ge Y, et al. Triglyceride-glucose index as a marker for visceral obesity in patients with gastric cancer [J]. Front Nutr, 2024, 11: 1515918.
[2]
Pati S, Irfan W, Jameel A, et al. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management [J]. Cancers (Basel), 2023, 15(2): 485.
[3]
Hermans MP, Ahn SA, Rousseau MF, et al. Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes [J]. Diabetes Metab, 2009, 35(6): 484-489.
[4]
Maeyens LT, Nelson JF, Zhao S, et al. Visceral adiposity, metabolic health and aging [J]. Nat Aging, 2026, 6(3): 506-519.
[5]
Jaroch A. Metabolomics of abdominal adipose tissue samples collected from patients with obesity - a critical review [J]. Mol Cell Biochem, 2026, 481(1): 29-39.
[6]
Zhang X, Lu X, Pan X, et al. Role of waist circumference-to-height ratio in assessing adiposity, predicting type 2 diabetes mellitus and other cardiometabolic diseases [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2024, 49(7): 1062-1072.
[7]
Sun Y, Lin X, Zou Z, et al. Association between visceral fat area and metabolic syndrome in individuals with normal body weight: insights from a Chinese health screening dataset [J]. Lipids Health Dis, 2025, 24(1): 57.
[8]
Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp [J]. J Clin Endocrinol Metab, 2010, 95(7): 3347-3351.
[9]
Tatsumi Y, Nakao YM, Masuda I, et al. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan [J]. BMJ Open, 2017, 7(1): e013831.
[10]
Knowlden AP, Wilkerson AH, Dunlap KB, et al. Systematic review of electronically delivered behavioral obesity prevention interventions targeting men [J]. Obes Rev, 2022, 23(9): e13456.
[11]
Peprah Osei E. Prevalence and predictors of prediabetes/type 2 diabetes mellitus among adolescents in the United States: NHANES (2021-2023) [J]. PLOS Glob Public Health, 2026, 6(2): e0005596.
[12]
Itani L, El Ghoch M. Waist-to-Height Ratio Cut-Off Points for Central Obesity in Individuals with Overweight Across Different Ethnic Groups in NHANES 2011-2018 [J]. Nutrients, 2024, 16(22): 3838.
[13]
Wei W, Zhang X, Zhou B, et al. Effects of female obesity on conception, pregnancy and the health of offspring [J]. Front Endocrinol (Lausanne), 2022, 13: 949228.
[14]
Kholmatova K, Krettek A, Dvoryashina IV, et al. Waist-to-Height Ratio-Reference Values and Associations with Cardiovascular Risk Factors in a Russian Adult Population [J]. Diabetes Metab Syndr Obes, 2025, 18: 2641-2653.
[1] 谭进富, 管春菠, 朱文. 腹腔镜下袖状胃切除术[J/OL]. 中华普通外科学文献(电子版), 2026, 20(03): 175-175.
[2] 王伦, 周昕, 宁伟伟, 杨清旭, 胡旭, 何诣航, 谢铭. 我国腹腔镜减重代谢手术后营养不良及管理[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(01): 9-11.
[3] 康星, 俞杭, 单晓东, 孙喜太, 褚薛慧. 单孔腹腔镜袖状胃切除术围手术期血液管理措施的比较研究[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(01): 18-21.
[4] 陈嘉林, 余绍辉, 李如春, 周太成. 基于倾向得分匹配法研究内脏脂肪面积与结直肠癌术后切口疝的相关性[J/OL]. 中华疝和腹壁外科杂志(电子版), 2026, 20(04): 379-385.
[5] 周哲琦, 艾克拜尔·艾力, 李义亮, 麦麦提艾力·麦麦提明, 玉素江·图荪托合提, 克力木·阿不都热依木. 机器人辅助与腹腔镜袖状胃切除联合胃底折叠及食管裂孔疝修补术的临床疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2026, 20(03): 259-264.
[6] 王家轩, 苟浩博, 魏秋亚, 高田宇, 樊勇. 单孔袖状胃切除联合单吻合口胃回肠转流术的临床疗效[J/OL]. 中华腔镜外科杂志(电子版), 2026, 19(02): 110-114.
[7] 赵媛媛, 李云雷, 杜鹏. 缺氧环境下肥胖相关蛋白对胶质母细胞瘤增殖的作用及机制研究[J/OL]. 中华神经创伤外科电子杂志, 2026, 12(02): 73-80.
[8] 马博, 李涛, 董扬帆, 商少华, 马华, 王俊, 纪文静. 减重代谢手术改善2型糖尿病肥胖患者胃肠肽及血糖的前瞻性研究[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(01): 53-60.
[9] 肖玉新, 阿衣加马力·衣马木, 热孜亚·艾合买提, 佟钙玉, 邹韶红. 超重/肥胖青少年双相障碍患者的睡眠呼吸障碍与心血管风险特征及相关性分析[J/OL]. 中华临床医师杂志(电子版), 2025, 19(11): 839-847.
[10] 王青青, 王秋凤, 尼玛, 梁亚婷, 陈晓宇, 刘强, 侯红瑛, 韩振艳. 高海拔地区孕妇妊娠晚期非空腹甘油三酯-葡萄糖指数与巨大儿之间的关系[J/OL]. 中华产科急救电子杂志, 2026, 15(03): 158-166.
[11] 胡传萌, 孙海玲, 伊鹏飞. 甘油三酯-葡萄糖指数与骨健康相关性研究进展[J/OL]. 中华诊断学电子杂志, 2026, 14(02): 138-143.
[12] 杨兴源, 向婷, 周庆. 腹腔镜袖状胃切除术与Roux-en-Y胃旁路术对肥胖合并阻塞性睡眠呼吸暂停患者术后代谢及胃食管反流病影响的研究进展[J/OL]. 中华胃食管反流病电子杂志, 2026, 13(01): 49-55.
[13] 张晓会, 刘芳, 刁英飞, 李岳瀛, 李艳玲. 基于人体成分分析探讨相位角与腹型肥胖的关联研究[J/OL]. 中华肥胖与代谢病电子杂志, 2026, 12(01): 9-15.
[14] 吴舒薇, 伍俊蓉, 刘冯园. 玛仕度肽对糖尿病及非糖尿病肥胖人群减重疗效和安全性的Meta分析[J/OL]. 中华肥胖与代谢病电子杂志, 2026, 12(01): 50-61.
[15] 杨磊, 熊见武, 沈宗文, 陈熊熊, 李滢旭. 腹腔镜胃袖状切除术后门静脉-肠系膜静脉血栓形成1例报道[J/OL]. 中华肥胖与代谢病电子杂志, 2026, 12(01): 72-77.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?